UK's Indivior shares tumble on lower 2025 revenue forecast (updated)
20/02/2025 08:50
(Adds shares in paragraph 2, CEO comment in paragraph 3,
company context in paragraph 4)
Feb 20 (Reuters) - British drugmaker Indivior INDV.L
on Thursday projected a 17% fall in 2025 net revenue at the
midpoint of its forecast range, partly hurt by weak sales of its
film-form medication-assisted therapy for opiate addiction,
sending its shares sharply lower.
Shares in the company fell as much as 22.8% to a near
four-month low of 670.5 pence in early trade.
CEO Mark Crossley said the steep fall expected in 2025 net
revenue was primarily due to a more than 50% drop at its opiate
addiction therapy, Suboxone film, amid intense generic pricing
pressures and the potential entry of a fifth generic competitor.
In October last year, Indivior issued its second profit and
revenue warning in three months citing weak sales of its opioid
addiction treatment Sublocade due to competition from Swedish
pharmaceutical firm Camurus' CAMX.ST drug Brixadi.
Indivior, which has a market value of just over 1 billion
pounds ($1.26 billion), reported a 16% rise in adjusted
operating profit to $312 million for the year ended December 31,
2024.
After a 9% increase in net revenue to $1.19 billion last
year, the company expects between $955 million and $1.03 billion
for 2025.
($1 = 0.7935 pounds)
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by
Subhranshu Sahu)
((abyjose.koilparambil@thomsonreuters.com;))